Aileron Therapeutics closes $33M to launch clinical trials for solid tumor drug
A new class of cancer drugs called “stapled peptides” has attracted a nice chunk of venture dollars. Cambridge biotech Aileron Therapeutics – the prime player in this space – just secured $33 million in investment, bringing its total Series E round up to $48 million. The funding will bring Aileron candidate ALRN-6924 – a drug that works to […]